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ABSTRACT 
 
Heterotaxy refers to the abnormal arrangement of internal organs in relation to 
each other. Model organism studies have shown that functions of more than eighty 
genes are required for normal asymmetric left-right organ development. CRELD1 has 
been shown to be necessary for proper heart development and mutations in CRELD1 
are known to increase risk of cardiac atrioventricular septal defects (AVSD). AVSD 
is the most common form of heart defect associated with heterotaxy, and we have 
previously shown that some individuals with heterotaxy-related AVSD have 
mutations in CRELD1.  
Therefore, we propose to examine the CRELD1 gene in a large sample of 
patients with heterotaxy syndrome. Our goal was to determine if mutations in 
CRELD1 are associated with other manifestations of heterotaxy or if they only 
coincide with AVSD. To achieve this aim, a sample size of 126 patients with 
heterotaxy collected by Dr. Belmont, Baylor college of Medicine, Texas, with 
approximately 66% of the heterotaxy population with different types of heart defects, 
were used for this study. Ten exons, promoter regions, and regulatory elements in the 
introns of CRELD1 gene were sequenced and analyzed.  
In this study three different heterozygous missense mutations in CRELD1 were 
identified in three unrelated individuals. These three individuals were diagnosed with 
different forms of heart defects in addition to AVSD. All three mutations were 
identified in highly conserved regions of CRELD1 possibly altering the CRELD1 
properties. This demonstrates that mutations in CRELD1 may increase the 
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susceptibility of AVSD in heterotaxy population. This information can help us to find 
factors effecting disease susceptibility in heterotaxy patients since the heart defects are 
a complex trait with incomplete penetrance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
Dedication 
 
This thesis is dedicated to my dear parents, who offered 
their unconditional love and support throughout this 
adventure and always encourage me to go through 
challenges. 
 iv
Acknowledgements 
First and foremost I would like to thank my thesis committee for their expertise and 
guidance: Dr. Deborah Duffield, Dr. Cheryl Maslen, and Dr. Suzanne Estes. I am eternally 
grateful and appreciate the support from Maslen lab members, Dr. Jennifer Redig, Darcie 
Babcock, and Ben Reshey. I would also like to thank Dr. John Belmont from Baylor College 
of Medicine for providing the samples for this study and Dr. Subrata Dey for collaboration. 
Funding for this project was granted by NIH R01083300, ULI RR024140, and Oregon 
Clinical Translational Research Institute. Finally, I thank my loving family, Sophia Trieu, Yun 
Xin Lim and other dear friends who embraced this project with me.  
 v
TABLE OF CONTENTS 
ABSTRACT…………………………………………………………………………….i 
DEDICATION…………………………………………………………………..…….iii 
ACKNOWLEDGEMENTS…………………………………………………………...iv 
LIST OF TABLES………………………………………………………………..…..vii 
LIST OF FIGURES……………………………………………………………….....viii 
LIST OF ABBREVIATIONS……………………………………………………......ix 
 
CHAPTER I: INTRODUCTION ................................................................................... 1 
1.1-HETEROTAXY AND PHENOTYPIC CHARECTRISTICS ..................... 1 
1.2-EPIDEMIOLOGY AND INHERITANCE OF HETEROTAXY AND 
OTHER DISORDERS OF L-R ASYMMETRY ................................................ 3 
1.3-L-R AXIS ESTABLISHMENT DURING EMBRYONIC 
DEVELOPMENT ............................................................................................... 5 
1.4-CLINICAL AND PRENATAL EVALUATION OF HETEROTAXY ........ 9 
1.4.1-THE CLINICAL EVALUATION OF HETEROTAXY ............... 9 
1.4.2-PRENATAL EVALUATION ..................................................... 11 
1.5-GENETIC RISK FACTORS AND MOLECUALR DIAGNOSTICS ....... 12 
1.5.1-ZINC FINGER PROTEIN ZIC3 ................................................. 12 
1.5.2-NODAL, LEFTYA, CRYPTIC, AND ACVR2B ............................ 14 
1.5.3-OTHER RISK FACTORS ........................................................... 17 
1.6-CRELD1 AS A CANDIDATE GENE ........................................................ 17 
1.7-HYPOTHESIS ........................................................................................... 21 
 
CHAPTER II: METHOD AND MATERIALS ............................................................ 22 
2.1-CLINICAL EVALUATION AND SAMPLING ........................................ 22 
2.2-DESIGN OF OLIGONUCLEOTIDE PRIMERS ....................................... 22 
2.3-PCR AMPLIFICATION ............................................................................ 23 
2.4-PURIFICATION OF PCR PRODUCTS .................................................... 24 
2.5-SEQUENCE ANALYSIS .......................................................................... 25 
2.6-ALLELE-SPECIFIC PCR .......................................................................... 26 
2.7-POLYMORPHISM PHENOTYPING (POLYPHEN-2)............................ 27 
 vi
CHAPTER III: RESULTS ............................................................................................ 28 
3.1-PATIENT1-A206T MUTATION .............................................................. 29 
3.2-PATIENT2-T265A MUTATION .............................................................. 32 
3.3-PATIENT3-R329C MUTATION .............................................................. 35 
3.4-OTHER SIGNIFICANT VARIANTS IN CRELD1 ................................... 36 
CHAPTER IV: DISCUSSION ..................................................................................... 39 
REFERENCES ............................................................................................................. 47 
APPENDIX: CRELD1 GENOMIC SEQUENCE ......................................................... 57 
 vii
LIST OF TABLES 
 
Table 1.1: Congenital anomalies associated with heterotaxy ......................................... 2 
Table 2.1: Oligonucleotide primers for CRELD1 exon amplication by PCR .............. 24 
Table 2.2: Template quantities for 1Xcycle-sequencing run ........................................ 25 
Table 2.3: Oligonucleotide primers for CRELD1 exon sequencing ............................. 25 
Table 2.4: ASP primer sequence .................................................................................. 26 
Table 3.1: The frequency of different abnormalities found in heterotaxy population of 
study ............................................................................................................................. 29 
Table 3.2: Non-synonymous variants in CRELD1 found in heterotaxy patients ......... 38 
 
 viii 
LIST OF FIGURES 
Figure 1.1: Overview of L-R asymmetry in mouse embryo  ......................................... 6 
Figure 1.2: Mice embryo at the developmental stage ................................................... 20 
Figure 3.1: CRELD1 protein and the relative position of amino acids ........................ 30 
Figure 3.2: Sequence analysis identifying first missense mutation in CRELD1. ......... 31 
Figure 3.3: Diagrammatic representation of CRELD1 protein .................................... 32 
Figure 3.4: Illustration of different heart defects .......................................................... 33 
Figure 3.5: Sequence analysis identifying second missense mutations in CRELD1 .... 34 
Figure 3.6: Sequence analysis identifying third missense mutations in CRELD1 ....... 36 
Figure 4.1: Approximate ratio of heterotaxy patients diganosed with heart defects and 
without heart defects ..................................................................................................... 39 
Figure 4.2: Alanine and threonine chemical structure .................................................. 41 
Figure 4.3: Arginine and cysteine chemical structure .................................................. 43 
Figure 4.4: Diagrammatic representation of the two cb-EGF domain of CRELD ....... 45 
 
 ix
LIST OF ABBREVIATIONS 
 
A-P: Anterior-posterior 
ALK: Activin-like receptors 
ASD: Atrial septal defects 
ASP: Allele specific PCR 
AVSD: Atrioventricular septal defects 
BBS: Bardet-Biedl syndrome 
CHD: Congenital heart defects 
CoA: Coarctation of the aorta 
CRELD: Cysteine rich with EGF like domains 
D-V: Dorsal-ventral 
DILV: Double inlet left ventricle 
DMSO: Dimethyl sulfate 
dNTP: Deoxynucleotide triphosphate 
EGF: Epidermal growth factor 
FGF: fibroblast growth factor 
L-R: Left-right 
LPM: Lateral plate mesoderm 
MGA: Malposition of great arteries 
PCD: Primary ciliary dyskinesia 
PCR: Polymerase chain reaction 
SNP: Single nucleotide polymorphism 
 x
TGA: Transposition of great artery 
TGF: Transcription growth factor 
cb-EGF: Calcium binding-EGF 
VCFS: Velo-Cardio-Facial syndrome 
VSD: Ventral septal defects 
ZFDs: Zinc finger domains 
 
 1
CHAPTER I: INTRODUCTION 
1.1-HETEROTAXY AND PHENOTYPIC CHARACTERISTICS 
Heterotaxy (hetero meaning ‘other’ and taxy meaning ‘arrangement’) refers 
to an abnormal developmental condition characterized by randomized arrangement 
of the thoracic and/or abdominal visceral organs, including the heart, lungs, liver, 
stomach, and spleen. The organs are either located randomly with respect to the left-
right (L-R) axis or to one another. This genetic disorder is characterized by multiple 
congenital malformations and complex cardiovascular malformation that is reported 
to be the major cause of morbidity and mortality in this population (Table1.1). 
Heterotaxy accounts for approximately 3% of all congenital heart defects 
(CHD) with an approximate prevalence of 1:10,000 live births (Lin et al., 2000), 
most frequently diagnosed in the newborn mainly due to cyanotic congenital heart 
disease (Sutherland and Ware, 2009). In individuals with heterotaxy any internal 
organ that is asymmetrically positioned can be abnormal and the midline defect, 
which results from disclosure of neural tube, occurs in approximately 40% of 
patients (Zhu et al., 2006). The wide phenotypic spectrum seen in heterotaxy, in 
combination with the lack of formal clinical guidelines for the evaluation, has made 
the identification of patterns of laterality defects more complicated. Thus these 
patients require an extensive diagnostic evaluation and multiple imaging studies in 
order to define their anatomy as well as chromosome microarray analysis due to 
associations with chromosome abnormalities. 
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Table 1.1: Congenital anomalies associated with heterotaxy (Zhu et al., 2006) 
 
Cardiovascular Atrioventricular discordance 
Atrial isomerism 
Double outlet right ventricle 
Pulmonary stenosis or atresia 
Transposition of the great arteries 
Single ventricle 
Left ventricular outflow tract 
obstruction 
Septal defects 
Total/partial anomalous venous 
return 
Interrupted inferior vena cava 
Bilateral superior vena cava 
Conduction system abnormalities 
 
Gastrointestinal 
 
 
 
              Extrahepatic biliary atresia 
Intestinal malrotation 
Omphalocoele 
Duodenal atresia/obstruction 
Tracheoesophageal fistula 
Annular pancreas 
Microgastria 
Midline liver 
Right-sided stomach 
 
Pulmonary Hyparterial or eparterial bronchi 
Impaired mucociliary clearance in 
patients with ciliary defect 
 
Central nervous system Neural tube defect 
 
Genitourinary/anal 
 
 
Imperforate anus 
Sacral dysplasia 
Renal dysplasia 
Horseshoe kidney 
Fused adrenal glands 
Bifid or septate uterus and vagina 
Musculoskeletal Vertebral and rib anomalie 
Immune Asplenia or polyspleni 
Ear, Nose, and Throat  Cleft palate 
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1.2-EPIDEMIOLOGY AND INHERITANCE OF HETEROTAXY AND OTHER DISORDERS OF L-
R ASYMMETRY 
Situs inversus, referring to complete mirror image arrangement of all internal 
organs, is estimated to occur in 1 in 8,000-25,000 individuals and is mainly due to 
abnormal cilia function or absent of cilia lining the respiratory tract known as 
primary ciliary dyskinesia (PCD). PCD is also associated with a wide variety of 
human diseases such as bronchitis, infertility, hydrocephalus, anosmia, and retinitis 
pigmentosa (Afzelius et al., 2001; Pan et al., 2005), and has an autosomal recessive 
inheritance pattern.  
Situs ambiguous, which refers to abnormal arrangement of internal organs 
with discordance of thoracic and visceral anatomy is mainly characterized by 
congenital anomalies and is estimated to take place in 1:10,000 live births (Lin et al., 
2000). Most cases of situs ambiguous occur sporadically and do not follow obvious 
Mendelian inheritance patterns, although phenotypic characterization of families 
suggests both autosomal recessive and dominant patterns with incomplete penetrance 
due to evidence of familial clustering. Family studies have identified isolated cardiac 
defects, isolated neural tube defects, or abnormal vasculature in unaffected 
individuals (Morelli et al., 2001).  
Laterality defects, which refer to any deviation from situs solitus including 
the failure to generate asymmetry, can arise in a single individual (Kosaki and Casey, 
1998; Winer-Muram, 1995) but are especially associated with monozygotic 
twinning. Environmental factors such as exposure to drugs or chemicals such as 
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nitrous oxide, retinoic acid, phenylephrine, methoxamine, have been reported to 
associate with L-R phenotypes in animal models (Levin, 2005).  
Isolated dextrocardia, which refers to right-sided heart position, showed a 
strong association with a family history of CHD and extracardiac anomalies. A 
population based study of cardiovascular malformation indicated that maternal 
diabetes and first trimester cocaine use are associated with heterotaxy (Kuehl and 
Loffredo, 2002). 
Heterotaxy most often occurs as a sporadic condition. Genetic mechanisms 
underlying heterotaxy are still not completely known, but the familial studies have 
suggested a complex inheritance or autosomal dominant and autosomal recessive 
inheritance with reduced penetrance and variable expressivity. (Vitale et al., 2001; 
Belmont et al., 2004; Zhu et al., 2006; Wessels et al., 2008).  
X-linked inheritance is well documented in heterotaxy and is caused by 
mutations in ZIC3 (Gebbia et al., 1997).  A large number of genetic syndromes and 
chromosome abnormalities have been associated with heterotaxy, including 
aneuploidies, complex chromosomal rearrangements, and microdeletions (Bisgrove 
et al., 2003; Ware and Belmont, 2008; Song et al., 2009). Reported examples are 
patients with trisomy 13 or trisomy 18. In addition, a number of submicroscopic 
chromosomal deletions, including 22q11.2 DiGeorge/Velocardiofacial Syndrome 
(VCFS) syndrome, have been identified in patients with heterotaxy. Bisgrove et al. 
(2003) reviewed unbalanced translocations, terminal deletions, inversions, and more 
complex chromosomal rearrangements associated with heterotaxy.  
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Analysis of genes located within submicroscopic chromosomal imbalances in 
patients with abnormal L–R asymmetry should be a useful tool in uncovering novel 
genetic pathways in laterality defects. However, it is not yet clear what percentage of 
isolated cardiac defects are mechanistically related to early L-R patterning 
abnormalities. In addition, the true incidence of human L-R patterning defects is not 
yet known and so further definition of the molecular basis may identify a higher 
incidence that has been recorded and a better understanding of this genetic disorder.   
 
1.3-L-R AXIS ESTABLISHMENT DURING EMBRYONIC DEVELOPMENT 
The congenital disorder in patients with heterotaxy mainly results from 
failure to establish normal L-R asymmetry during embryonic development, with 
major morbidity and mortality resulting from complex cardiovascular malformations 
(Sutherland and Ware, 2009). The L-R asymmetry of the heart is closely connected 
to its function and alteration in cardiac situs represent a significant source of human 
heart malformations (Kathiriya and Srivastava, 2000). Since the L-R axis is 
established during early development, a basic understanding of an embryonic tissues 
and molecular events involved in L–R axis formation is beneficial for initiating a 
diagnostic work-up, understanding the genetic basis of disease, and assessing 
recurrence risk. 
The L-R axis is established early in embryogenesis subsequent to the 
development of anterior-posterior (A-P) and dorsal-ventral (D-V) axes. Recent work 
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with model organisms has offered a detailed view of the steps taken to establish 
asymmetry in the vertebrate (Bisgrove and Yost, 2001). In Fig.1.1, five steps in 
developing L-R asymmetry in the mouse embryo are illustrated. The early stage of 
L-R patterning occurs before cilia are established at the node, a transient embryonic 
organizer. This involves processes such as planar cell polarity in which asymmetric 
gradients are established within a cell, across a sheet of cells and ultimately 
throughout the embryo (Aw and Levin, 2009). The signaling pathways and the 
molecular mechanisms of early stage of L-R patterning during embryogenesis are not 
yet well defined and may vary by model organism (Sutherland and Ware, 2009). 
 
Figure 1.1: Overview of L-R asymmetry in mouse embryo (Sutherland and Ware, 2009). Evidence 
shows intercellular asymmetry involving mechanism such as Planar cell polarity (PCP) take place 
before the establishment of the node or cilia. During the second stage, the node and functioning motile 
cilia form. Centrally located monocilia are motile and peripheral monocilia lack L–R dynein and are 
immotile. In the next stage, the movement of cilia at the node creates a leftward flow of morphogens. 
Nodal expression is initially bilateral, but becomes asymmetrically expressed on the left, providing 
molecular evidence of L–R asymmetry. During the stage four, Nodal signal is propagated from the 
node to the lateral plate mesoderm (LPM) where asymmetric gene expression is established. In stage 
five, asymmetric signaling is propagated from the LPM to organ primordia in order for proper 
morphogenesis to occur. 
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During the second stage of mouse embryo development, the node and 
functioning motile and sensory cilia form. The genetic control of node 
morphogenesis is unknown but it has been proven that Notch signaling, which allows 
a cell-cell communication, is necessary for both proper node structure as well as later 
asymmetric nodal expression (Krebs et al., 2003; Przemeck et al., 2003; Takeuchi et 
al., 2007). In addition, at this stage the monocilia located at center are motile 
compare to immotile peripheral monocilia (McGrath et al., 2003). This characteristic 
allows the movement of cilia at the node, creating a leftward flow of morphogens, 
which form the clockwise rotational motion of the cilia and creating a unidirectional 
flow in stage 3, which is essential for proper L-R asymmetry (Sutherland and Ware, 
2009). 
In the next stage, as results of leftward flow of cilia, fibroblast growth factor 
(FGF) signaling triggers the releases of particles carrying the morphogens Sonic 
hedgehog and retinoic acid, which are pushed to the left of the node and trigger a 
cascade of gene expression (Okada et al., 2005; Hirokawa et al., 2006).  In addition, 
the unidirectional flow of extracellular fluid bends the peripheral immotile cilia 
surrounding the node, resulting in an asymmetric cytoplasmic calcium flux (McGrath 
et al., 2003). These two pathways effect Nodal expression which initially is bilateral, 
but becomes asymmetrically expressed on the left, providing the first molecular 
evidence of L-R asymmetry which is critical for subsequent left-sided gene 
expression in the lateral plate mesoderm (LPM) (Sutherland and Ware, 2009).  
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In stage four, Nodal signal transduction pathway expressed in the left side of 
the node and the signal is propagated to the LPM where asymmetric gene expression 
is established. At the presence of an EGF-CFC cofactor, Nodal signals through type I 
and type II receptors and activates two antagonists Lefty-1 (LEFTYA in human) and 
Lefty-2 (LEFTYB in human) which are expressed in the midline and in the LPM, 
respectively. This activation limits Nodal expression and subsequently inhibits the 
transfer of left-sided gene expression across the midline of the embryo. Pitx2, a 
homeobox transcription factor, is also activated by Nodal and is asymmetrically 
expressed in the LPM as well as in various organs. This molecular asymmetry is 
much conserved across vertebrates and the majority of the known human heterotaxy 
mutations have been discovered in this pathway. However, mutations within this 
pathway cause heterotaxy in a minority of cases, indicating that novel genetic 
etiologies remain to be determined (Sutherland and Ware, 2009). 
In the final stage, asymmetric signaling is propagated from the LPM to organ 
primordia in order for proper morphogenesis to occur. The asymmetric Pitx2 
expression persists after the disappearance of the Nodal signal, and involves in 
organogenesis in the heart, gut, and lungs, demonstrating asymmetric expression in 
developing organ primordia. Information about cardiac specific targets during 
looping morphogenesis is currently lacking and needs further investigation. 
Study of L-R asymmetry using model organism has shown that heterotaxy 
may result from defects in any of these five steps. Isolated dextrocardia or CHD 
related to abnormal laterality can also result from abnormalities at various stages of 
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L-R patterning. However, a detailed genetic mechanism of the pathway is still 
remains to be determined. 
1.4-CLINICAL AND PRENATAL EVALUATION OF HETEROTAXY 
1.4.1-The clinical evaluation of heterotaxy 
Although heterotaxy shows broad phenotypic variability, the approach to 
studying this population is relatively straightforward. The first and most important 
step during clinical evaluation of laterality defects is to identify the full phenotypic 
spectrum of abnormalities in the proband and to determine whether it is a case of 
situs inversus or situs ambiguous. This information is essential for patient 
management as well as providing information that is critical for identification of the 
possible underlying genetic etiology. 
Patients with situs inversus should have evaluation of ciliary function. In 
addition the signs of Bardet-Biedl syndrome (BBS), including obesity, retinitis 
pigmentosa, and mental retardation, should be evaluated. Although situs inversus is 
infrequently reported in BBS, it occurs at a significantly higher rate than in the 
general population (Ansley et al., 2003). Mutations in BBS2 and BBS8 have been 
reported in association with situs inversus. Five out of eight known BBS genes 
encode basal body or cilia proteins, implying a potential for laterality defects 
(Beales, 2005). Infantile nephronophthisis is another genetic disorder that is 
associated with situs inversus. This is an autosomal recessive cystic kidney disease 
which is caused by mutations in INVERSIN (Otto et al., 2003). Lacking evidence of 
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cystic kidneys or stigmata of BBS, a patient with situs inversus is classified as having 
PCD, previously known as immotile cilia syndrome, and therefore and should be 
followed by a pulmonologist or allergist/immunologist as needed (Zhu et al., 2006). 
Patients with situs ambiguous require an extensive diagnostic evaluation 
directed toward defining the anatomy and preventing potential complications. The 
evaluations tailored based on data collected from performing an echocardiogram 
and/or cardiac MRI, abdominal and renal ultrasound, and vertebral X-rays. In 
addition, the spleen should be evaluated by ultrasound and a peripheral blood smear 
to detect the presence or absence of Howell-Jolly bodies, red blood cell inclusions 
indicating abnormal spleen function. 
A three-generation pedigree is an essential component of the evaluation. For 
situs ambiguous, any family history of congenital anomaly is potentially 
contributory. In addition, mouse models suggest that increased pregnancy loss may 
be associated with mutations in genes responsible for L-R patterning (Zhu et al., 
2006). In addition, there are large numbers of other syndromes that are associated 
with laterality defects that can be used for clinical evaluation (Aylsworth, 2001). 
Among aneuploidies, both trisomy 13 and trisomy 18 can cause congenital anomalies 
overlapping situs ambiguous that can potentially complicate prenatal counseling if 
amniocentesis is not performed (Ware and Belmont, 2004). Microdeletion 22q11.2 
can be detected by karyotype which is associated with laterality defects (Aylsworth, 
2001). It is likely that a number of complex malformation syndromes result from 
early developmental patterning defects in which laterality can be disrupted. 
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1.4.2-Prenatal evaluation 
The frequency of identified heterotaxy cases on prenatal ultrasound has 
increased as the result of advances in imaging technology (Berg et al., 2003).  For 
example, fetal echocardiography has provided a tool for detailed study of the 
structure of an unborn baby’s heart. Early fetal heart block is commonly associated 
with left isomerism and early detection of the disorder is critical for clinical 
management (Jaeggi et al., 2005). In the absence of a syndromic diagnosis, the 
prognosis of the fetus is largely based on the cardiac anatomy and/or the presence of 
biliary atresia. Biliary atresia is a disorder of infants in which there is progressive 
obliteration or discontinuity of the extrahepatic biliary system, resulting in 
obstruction of bile flow, requiring liver transplantation within the first year of life 
(Leyva-Vega et al., 2010).  Biliary cystic malformations can be identified prenatally 
and, although not specific for biliary atresia, are highly suspicious when identified in 
conjunction with other laterality defects. Since the inheritance patterns of heterotaxy 
is very complicated and varies among individuals, genetic counseling in prenatal 
cases is complex. In addition to discussion of the anatomic defects and their 
prognosis and management, counseling sessions should also include discussion of 
both syndromic and nonsyndromic possibilities and an explanation of inheritance 
patterns. However, to gain a better understanding of these disorders, analysis of 
genes involve in L-R asymmetry would be a powerful tool in uncovering novel genes 
and pathways in laterality defects.  
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1.5-GENETIC RISK FACTORS AND MOLECULAR DIAGNOSTICS 
Model organism studies have shown that functions of more than eighty genes 
are required for normal asymmetric L-R organ development. While some of these 
genes probably have a conserved function in humans and any mutation in them are 
lethal, mutations in relatively few genes have been identified in patients with 
heterotaxy. These include ZIC3, LEFTYA, CRYPTIC and ACVR2B, and single cases 
of mutations in NKX2.5 and CRELD1 have been reported in patients with 
dextrocardia (Watanabe et al., 2002; Robinson et al., 2003). The contribution of 
mutations in these genes to heterotaxy or L-R patterning defects in the heart remains 
to be characterized further in larger sample sets (Zhu et al., 2006). In all these 
mutation studies, conventional methods of assessing the role of particular rare 
variants as mutations have been used. This usually includes analysis of controls for 
the particular variant. However, there is very little power to repeatedly detect rare 
variants, even in very large control sets.  
 
1.5.1-Zinc finger protein ZIC3 
The zinc finger domains (ZFDs) of the Zinc family proteins have been 
strongly conserved over the evolution of a broad range of eumetazoan animals 
(Aruga et al., 2006) suggests they provide the structural basis for the essential roles 
of Zic family protein in animal development (Aruga, 2004; Herman and El-Hodiri, 
2002).  In humans there are five members of the ZIC family that are involved in 
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congenital anomalies (Grinberg and Millen, 2005). One of them, ZIC3, was the first 
gene identified to have a casual role in defects in human laterality (Ferrero et al., 
1997; Gebbia et al., 1997). Mutations in ZIC3, which is on the X chromosome, can 
cause the X-linked form of heterotaxy, HTX-1 (OMIM#306955).  
ZIC3 was first identified as a gene preferentially expressed in mouse 
cerebellum (Aruga et al., 1996) and has the ability to bind DNA and activate 
transcription (Mizugishi et al., 2001).  Zic3-deficient mice develop a broad range of 
abnormalities in addition to heterotaxy such as neural tube defects, skeletal 
patterning defects, cerebellar hypoplasia and abnormal behavior (Carrel et al., 2000; 
Klootwijk et al.,2000; Purandare et al., 2002; Aruga et al., 2004). 
ZIC3 protein is made of five tandemly repeated C2H2 zinc finger 
transcription factors that are involved in early patterning of the vertebrate embryo. In 
human, missense mutations that result in changes in cysteine 253 (C253S) or 
histidine 286 (H286R) are found in heterotaxy patients and cause extracellular 
localization of the mutant ZIC3 protein (Ware et al., 2004). Another mutation that 
alters a tryptophan residue (W255G) is associated with transposition of the great 
artery (TGA), a CHD that might be an expression of a L-R laterality disturbance 
(Chhin et al., 2007). Loss of function of this gene has also been reported to associate 
with other abnormalities such as double outlet right ventricle, and ventricular 
inversion (Sutherland and Ware, 2009). 
Approximately 1% of sporadic heterotaxy cases (male and female) are caused 
by mutation in ZIC3. In addition, affected females have been described with point 
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mutations or with chromosomal translocations at this gene(Megarbane et al., 
2000;Ware et al., 2004; Fritz et al., 2005; Tzschach et al., 2006; Chhin et al.,2007). 
Carrier females who are heterozygous for ZIC3 mutation are clinically unaffected 
although a subset has situs inversus (Casey et al., 1993; Gebbia et al., 1997). 
Deletion of the ZIC3 locus has been associated with situs ambiguous, suggesting the 
cause of pathogenesis in the patients with the point mutations (Ferrero et al., 1997).  
These findings have suggested that isolated CHD may be caused by genes 
involved in L-R axis development and that there may be variable expression of 
mutant alleles within and between families. It is currently unclear to what degree 
ZIC3 mutations contribute to sporadic heterotaxy, and this information is necessary 
to provide accurate counseling information to families. Mice models suggest that 
ZIC3 acts upstream of Nodal signaling at the node, however its detailed 
developmental function is not yet clear (Purandare et al., 2002; Ware et al., 2006). 
 
1.5.2-NODAL, LEFTYA, CRYPTIC, and ACVR2B 
NODAL is a member of the transcription growth faction (TGF)-β family and 
is involved in cell differentiation. The pattern of NODAL expression and its 
developmental function has largely conserved among vertebrates. In the mouse, it is 
known to have an essential role in early embryonic development including mesoderm 
and endoderm formation and L-R axis patterning. During gastrulation stage of 
development, NODAL is expressed in the epiblast and visceral endoderm, and it 
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induces its co-receptor Cripto, which controls A-P patterning. Lack of NODAL 
expression in mice causes the absence of primitive streak and loss of mesoderm 
formation (Conlon et al., 1994; Lowe et al., 1996; Zhou et al., 1993). The functions 
of NODAL have been examined in other species, and in all of them NODAL 
orthologs are expressed asymmetrically in the left side of the node as well as in left 
lateral plate mesoderm (Schier and Shen, 2000; Whitman, 2001). This data shows 
that the Nodal signaling cascade within the lateral plate mesoderm is required for L-
R patterning in vertebrates (Mercola and Levin, 2001; Hamada et al., 2002; Schier, 
2003), and any disturbance in expression of NODAL can lead to polarity reversal of 
visceral organs and heart looping (Harvery, 1998). Mutations in NODAL have been 
identified in patients with heterotaxy following an autosomal dominant inheritance 
pattern (Kosaki et al., 1999; Bamford et al., 2000; Goldmuntz et al., 2002; Selamet 
Tierney et al., 2007; Roessler et al., 2008; Mohapatra et al., 2009). 
Nodal signaling uses an Activin/TGF-β-like pathway mediated by several 
Activin-like receptors (ALKs). NODAL signals via ALK4 and AKL7 in association 
with either ActRIIA or ActRIIB (Whitman 2001). The activated receptor complex 
phosphorylates an intracellular receptor-regulator known as Smads. This 
phosphorylated complex binds to Smad4 and that results in its translocation to the 
nucleus (Attisano and Wrana, 2002). This complex then can either bind DNA 
directly or can interact with other DNA binding proteins such as transcription co-
activator FoxH1 to regulate the promoters of various genes. In addition, FoxH1 
regulates Nodal signaling pathway by binding to the NODAL and Lefty2 asymmetric 
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enhancer element (Saijoh et al., 2000). Mutations in several components of the Nodal 
signaling pathway in animal models has exhibit defects in L-R axis development 
(Pogoda et al., 2000; Yamamoto et al., 2001; Yan et al., 2002). Mutation in 
components of the Nodal signaling pathway, such as genes encoding the ligand 
(NODAL), ligand co-receptor (CFC-1), receptor (ACVRIIB), FOXH1, and midline 
inhibitor (LEFTYA) within the Nodal signal transduction pathway, have been 
identified in human heterotaxy (Kosaki et al., 1998; Bamford et al., 2000; Goldmuntz 
et al., 2002; Selamet Tierney et al., 2007; Roessler et al., 2008; Mohapatra et al., 
2009). Biochemical studies indicate that Cripto (TDGF1) and Cryptic (CFC1) in 
mouse and human form complexes with NODAL, ALK4/ALK7 and ActRIIB and act 
as a co-receptor for NODAL at the cell surface (Bianco et al., 2002; Yan et al., 
2000).  
Study on NODAL variants in 269 patients with heterotaxy or isolated 
cardiovascular observed missense mutations in 14 unrelated patients (Mohapatra et 
al., 2009). Functional analysis of the mutant proteins showed a decrease in Nodal 
signaling. Similarly, functional analysis of mutations in Cryptic (CFC1), a gene 
encoding an epidermal growth factor family protein, CFC1, which functions as a 
NODAL co-receptor, revealed abnormal cellular localization of the mutant protein 
(Bamford et al., 2000). ACVRIIB mutations were identified in 3 of 126 patients with 
left–right anomalies and mutations in LEFTYA were discovered in 2 patients (Kosaki 
et al.,1998). The study showed that each patient inherited the mutant allele from an 
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unaffected carrier parent, indicating autosomal recessive inheritance pattern or 
incomplete penetrance.  
 
1.5.3-Other risk factors 
With over hundred candidate genes identified through mouse models of L–R 
patterning defects, it is likely that significant genetic heterogeneity will be found in 
human heterotaxy. To date, the majority of genes identified have either not yet been 
tested in larger heterotaxy populations or have been found to have mutations at a low 
frequency (Watanabe et al., 2002; Robinson et al., 2003). For example, positional 
cloning of a region involved in a reciprocal translocation in one patient identified 
SESN1, a gene involved in L-R patterning. Functional analysis of this protein 
revealed that it plays a role in activating Nodal signaling. However, the prevalence of 
disease causing mutations in this gene is less than 1% based on an initial screen of a 
heterotaxy cohort (Peeters et al., 2003, Peeters et al., 2006). Efforts are ongoing to 
identify novel genes that cause or contribute to the heterotaxy phenotype. One of the 
candidate genes that require a large population study in patients with heterotaxy is 
CRELD1. Missense mutations in CRELD1 are associated with atrioventricular septal 
defects (AVSD), including AVSD in patients with heterotaxy (Robinson et al., 
2003).  
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1.6-CRELD1 AS A CANDIDATE GENE 
CRELD1 is the member of a highly conserved family of proteins known as 
CRELD (Cysteine Rich with EGF-Like Domains) (Rupp et al., 2002), that are 
members of the TGF-superfamily, which contains a diverse array of multifunctional 
cytokines. This group has one other homologous member, CRELD2. The two 
members of this family are nearly identical except that CRELD1 is a cell surface 
molecule, whereas CRELD2 is a secreted protein that is possibly a regulator of 
CRELD1 function. These cell-surface/extracellular proteins are characterized by 
tandemly repeated epidermal growth factor-like (EGF) domains and a unique motif 
called the CRELD domain.  
CRELD1 is located on chromosome 3p25 (Rupp et al., 2002) and is the first 
recognized risk factor for isolated AVSD (Robinson et al., 2003), a common 
congenital heart malformation affecting the atrioventricular valves and septa that 
results in a mixing of oxygenated and non-oxygenated blood. In addition, CRELD1 is 
becoming increasingly recognized as an important factor in cancer biology with 
numerous proposed biochemical interactions. 
CRELD1 missense mutations occur in almost 8% of individuals with AVSD 
(Robinson et al., 2003), and 5% of Down syndrome-associated AVSD cases (Maslen 
et al., 2006). The highly specific genetic association between CRELD1-missense 
mutations and AVSD suggests that mutations in CRELD1 significantly increase the 
risk of developing an AVSD. High level of incidence of AVSD has been reported in 
heterotaxy patients, presumably due to physical disruption of septation from 
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laterality defects. Missense mutations in CRELD1 suggest that defects in CRELD1 
may increase the likelihood of AVSD in heterotaxy (Robinson et al., 2003). 
However, a recent study on a CRELD1 knocked out (Creld1(-/-))  mice model 
indicates that CRELD1 is not associated with laterality defects in mice embryos 
(Redig et al., submitted). 
Fig.1.2 compares Creld1(-/-) mice embryos with a Creld1(+/-) and wild type 
Creld1(+/+) embryos. As can be seen, Creld1(-/-) embryos exhibited underdeveloped 
organs such as telencephalons and heart. However, the positions of organs is the 
same in Creld1(-/-) embryos relative to wild-type Creld1(+/+) with no sign of laterality 
defects.  This indicates that CRELD1 does not cause laterality defects (Redig et al., 
submitted), but it doesn’t rule out the possible role of CRELD1 as a risk factor for 
developing AVSD in a heterotaxy population. 
The basic biological function and definition of the CRELD1 biochemical 
pathway is under investigation. Multiple alternate splice variants of CRELD1 suggest 
that there are isoforms with diverse functions. CRELD1 can bind to RTN3, an 
apoptosis-inducing protein responsive to endoplasmic reticulum stress, and controls 
apoptosis activity of RTN3 (Xiang and Zhao, 2009). In addition, a recent study on 
cell migration during development suggests the important role of CRELD1 in 
polarized cell migration (Nystul et al., 2009), a process regulated by Notch signaling 
which is necessary for proper node structure as well as asymmetrical nodal 
expression.  
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   Creld1(+/+)                                           Creld1(+/-)                                         Creld1(-/-) 
     
    
Figure 1.2: Mice embryos at the developmental stage (Redig et al., submitted). The two picture on far 
left (A,A’) are showing the wild-type  embryo, two in the middle (B, B’)  are heterozygous for 
Creld1(+/-) and the two other on the far right(C,C’) are showing the nocked out mice Creld1(-/-) 
embryos. There is a broad abnormalities in Creld1(-/-) embryos  especially in the head, which exhibited 
underdeveloped telencephalons, T and underdeveloped olfactory placodes, OP. The position of Limb 
buds (LB), olfactory placode (OP), branchial arch (BA), telencephalon (T), heart (H) are indicating 
the absence of laterality defects in Creld1(-/-) embryos. 
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1.7-HYPOTHESIS 
Despite all of the indications that CRELD1 plays a role in human early 
development, no study has been done in large sample of patients with heterotaxy to 
determine if mutations in CRELD1 are a risk factor increasing the likelihood of 
AVSD in this population. To address this, we examined whether there is a significant 
difference between the variables in this population. Our hypothesis and alternative 
hypothesis are:  
• Hypothesis: there are missense mutations in CRELD1 which increase 
the likelihood of AVSD or other CHD in heterotaxy patients.  
• Alternative Hypothesis: there is no novel mutation in CRELD1 effecting 
susceptibility for CHD in this population. 
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CHAPTER II: METHOD AND MATERIALS 
2.1-CLINICAL EVALUATION AND SAMPLING 
The study sample included 126 individuals with a diagnosis of heterotaxy 
syndrome with or without heart defects, identified by the Baylor College of 
Medicine, Houston, Texas and provided in collaboration with Dr. John Belmont. The 
study population ranged broadly in age and sex. 
A biological sample for genomic DNA isolation was obtained from each 
individual, from blood or by buccal samples collected by mouthwash, by the 
Belmont group using standard technology. The normal control population DNA 
panels from Caucasian and Hispanic populations were obtained from the Coriell 
Repository (Camden, NJ).  
 
2.2-DESIGN OF OLIGONUCLEOTIDE PRIMERS 
The coding and known regulatory regions of CRELD1 were screened for 
point mutations by standard DNA sequencing of PCR amplified genomic DNA. PCR 
amplification was done using previously designed primers and conditions (Robinson 
et al., 2003). The primer sequences and amplification profiles are listed in table 2.1. 
Primers were used to amplify ten exons and two promoter regions as well as at least 
50 bp into introns from each junction in a total of seven amplicons. 
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2.3-PCR AMPLIFICATION 
For each patient genomic DNA sample, seven PCR reactions were performed 
using the primers listed in table 2.1. PCR reactions for regions including exon 3,4,10, 
and promoter region 2 were performed in a 25 µl reaction volume containing 100 ng 
of genomic DNA, 25 pmol of each primer, and 12.5 µl of Invitrogen AccuPrime™ 
PCR SuperMixII.  
For the rest of the exons and promoter region 1, PCR reactions were 
performed in a 25 µl reaction volume containing 100 ng of genomic DNA, 25 pmol 
of each primers, 5 µl of Herculase II buffer (5x), 2 µl of 10mm dNTPs, 1.25 µl of 
DMSO, 0.25 µl of Herculase II Polymerase (Stratagene; La Jolla, CA, USA). PCR 
cycling was carried out on a Veriti® Thermal Cycler (Applied biosystems, Ca, USA) 
using a denaturation cycle at 95 ºC for 2 min, followed by 35 cycles of denaturation 
at 95ºC for 15 sec and annealing (Table 2.1) 15 sec, and extension step at 72ºC for 30 
sec and a final extension step at 72ºC for 7 min. The products were visualized by 
standard ethidium bromide-agarose gel electrophoresis. 
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Table 2.1: Oligonucleotide primers for CRELD1 amplification by PCR. 
Amplicon Primer pair Annealing 
Temperature 
(ºC) 
Product 
size 
(bp) 
CRELD1 
Promoter 
Region 1 
 
Pro 1-F 5’ CTG CTT CGA CAG GCT 3’ 
Pro 1-R 5’ ATC CGG ATA TGA AGG 3’ 
62 685 
CRELD1 
Promoter 
Region 2 
 
Pro 2-F 5’ CGG TCG CTT CTT CCT TCT C 
Pro 2-R 5’ AGA AGA CTG GGG AGG TGG AG 3’ 
 
63 665 
CRELD1 
Exons 1-2  
E1-F 5’ AGC CTC TCC ACG CCC TCT A 3’ 
E2-R 5’ CCT AGC CCT ACA CCA GCA GAG 3’ 
 
62 600 
CRELD1 
Exons 3-4  
E3-F 5’ GAG ACT TGA GGA GGG TGG TG 3’ 
E4-R 5’ AAG CCT TTC CCC ACT GAT TT 3’ 
 
58 800 
CRELD1 
Exons 5-6  
E5-F 5’ TGT ATA GAT GAC CTC ACC TGG TTT 3’ 
E6-R 5’ CTG ACC ATC TTC CCA GAC CT 3’ 
 
58 400 
CRELD1 
Exons 7-8-9  
E7-F 5’ CTC TGG CTT CAG CTT CCC TA 3’ 
E9-R 5’ GCC TGC CTT CTC TTT GAA TG 3’ 
 
63 800 
CRELD1 
Exon 10  
E10-F 5’ CCA GGA ACA GGG ATA CGA GTG 3’ 
E10-R  5’ GGT GCT TAC CCC ACT CTC AAA 3’ 
 
58 400 
 
2.4-PURIFICATION OF PCR PRODUCTS 
Template quantity was adjusted based on the PCR product size (Table 2.2). 5 
µl of PCR product was purified using 2 µl of ExoSAP-IT® (United States 
Biochemical, Ohio, USA). The samples were incubated at 37°C for 15 min to 
degrade remaining primers and nucleotides followed by incubating at 80°C for 15 
min to inactivate ExoSAP-IT. 
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Table 2.2. Template quantities for 1X cycle-sequencing run 
Template Template quantity 
PCR product:  
100-200 bp 1-3 ng 
200-500 bp 3-10 ng 
500-1000 bp 5-20 ng 
 
2.5-SEQUENCE ANALYSIS 
The templates were sequenced in both directions using the sequencing 
primers, listed in Table 2.3, by the OHSU General Clinical Research Center DNA 
Sequencing Facility. The sequencing electropherograms were compared with gene 
sequences from GenBank accession number NM_001077415.1 using Mutation 
SurveyorTM DNA Analysis software (SoftGenetics LLC, Inc).  
Table 2.3: Oligonucleotide primers for CRELD1 exon sequencing 
Region Primer pair 
Promoter Region 1  Pro 1-F-Seq 5’ CTG CTT CGA CAG GCT 3’ 
Pro 1-R-Seq 5’ ATC CGG ATA TGA AGG 3’ 
Promoter Region 1 Pro 2-F-Seq 5’ CGG TCG CTT CTT CCT TCT C 
Pro 2-R-Seq 5’ AGA AGA CTG GGG AGG TGG AG 3’ 
 
CRELD1 Exons 1-2  E1-F-Seq 5’ CGC CCT CTA TCT GCA GGT CC 3’ 
E2-R-Seq 5’ GAG CAG AGA TTT GGC GGG GAG GGG A 3’ 
 
CRELD1 Exons 3-4  E3-F-Seq  5’ GGG TGG TGG GTG GGG TGG GGC 3’ 
E4-R-Seq  5’ CCC ATC TCC CCA GCC CTG TC 3’ 
 
CRELD1 Exons 5-6  E5-F-Seq 5’ CAC CTG CTT TGG TGT CTT CC 3’ 
E6-R-Seq 5’ TCC CAG ACC TAG CTA GGG CC 3’ 
 
CRELD1 Exons 7-8-9  E7-F-Seq  5’ TTC AGC TTC CCT ACT AAA TAG GG 3’ 
E9-R-Seq  5’ TCT TTG AAT GAG GAC CTC CC 3’ 
 
CRELD1 Exon 10  E10-F-Seq  5’ TAC GAG TGC CAG GCT GCA TC 3’ 
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2.6-ALLELE-SPECIFIC PCR (ASP) 
The Single Nucleotide Polymorphism (SNP) database was queried to identify 
DNA sequence alterations that were commonly accruing SNPs. In order to detect 
SNPs for missense amino acid changes found at exon 5, amino acid position A206T, 
first detected on sequencing data, allele-specific PCR analysis was used on the 
patient sample and control population.  
Genomic DNA was amplified by use of primers that match/mismatch one of 
the alleles at the 3’-end of the reverse primer (5’-CATACCAGATGGCTGGTG-3’ 
and 5’- CATACCAGATGGCTGGCG-3’, mutant and wild type, respectively). The 
reverse primers were coupled with upstream (forward) primer (5’- 
CTGGTTTGGTGTCTTCCC -3’). Characterization of this assay demonstrated that 
the wild-type exon 5 primer amplified genomic DNA from both the patient and 
normal controls, whereas the mutant primer was capable of amplifying only genomic 
DNA from the affected individual in whom the mutation had been characterized.  
Table 2.4: ASP primer sequence. 
 
Name Primer sequence PCR condition 
CRELD1-A206T-200-F CTG GTT TGG TGT CTT CCC 95 ºC x 2´ 
   95 ºC x 15´´ 
   62 ºC x 15´´ 
   72 ºC x 15´´  
72 ºC x 7´ 
CRELD1-A206T-2nd-mut-R CAT ACC AGA TGG CTG GTG 
CRELD1-A206T-2nd-WT-R CAT ACC AGA TGG CTG GCG 
CRELD1-T265A-2nd-mut-R CTC ATA GGA GCC CTC AGC 95 ºC x 2´ 
   95 ºC x 15´´ 
   60 ºC x 15´´ 
   72 ºC x 15´´  
72 ºC x 7´ 
CRELD1-T265A-2nd-WT-R CTC ATA GGA GCC CTC AGT 
CRELD1-T265A-200-F GGT TGG CAA ATG TGG TCT C 
x 40 
x 40 
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The DNA samples were amplified by PCR using 100 ng of genomic DNA in 
a 25 µl reaction containing 0.2 µl of 25 mM of each primer, 5 µl of Herculase II 
buffer (5x), 2 µl of 10mm dNTPs, 1.25 µl of DMSO, 0.25 µl of Herculase II 
Polymerase (Stratagene; La Jolla, CA, USA), and PCR cycling was carried out on a 
Veriti® Thermal Cycler (Applied biosystems, Ca, USA). Condition for PCR were 2 
min of initial activation step at 95 ºC followed by 40 cycles of  denaturation at 95 ºC 
for 15 sec and annealing at 62 ºC for 15 sec, and extension at 72 ºC for 30 sec and a 
final extension step at 72 ºC for 7 min. The products were visualized by standard 
ethidium bromide-agarose gel electrophoresis. In all cases the primers gave a single 
band of the expected size, 200 bp. 
 
2.7-POLYMORPHISM PHENOTYPING (POLYPHEN-2) 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) was used to predict 
possible impact of an amino acid substitution on the structure and function of 
CRELD1. Polyphen-2 is a bioinformatics tool which uses multiple algorithms to 
predict the impact of missense mutations on human protein structure. This tool 
allows the analysis of all human non-synonymous SNPs publicly available via SNP 
database.  
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CHAPTER III: RESULTS 
 
Out of 126 patients with heterotaxy, approximately 66% of them were also 
diagnosed with different type of heart defects (Table 3.1). DNA sequence analysis of 
CRELD1 in this cohort of 126 study subjects identified three different missense 
variants (A206T, R329C and T265A) in three unrelated individuals, who had no 
other mutations or rare variants identified in their genomes. A two base pair GA 
deletion was found in non-coding sequence of ten other patients in intron position 
9959990/1. Four previously characterized common polymorphic variants (rs279552, 
rs57022843, rs9853613, rs2302786) were also observed in this population but not 
investigated further. In addition, three other synonymous variants (L304L, P315P 
and Q368Q) previously seen by our laboratory in other studies were detected (Table 
3.2), but were not further characterized as they appeared to have no functional 
significance. 
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Table 3.1: The frequency of different abnormalities found in heterotaxy population of 
study. Other heart defects were including right sided cardiac apex, mesocardia, 
hypoplastic left heart syndrome, Left Atrial isomerism, double aortic Arch, L-loop 
Patent ductus arteriosus, double outlet right ventricle, hypoplastic left ventricle , and 
interrupted inferior vena cava 
Abnormality Number of patients 
ASD,VSD,AVSD with or without other heart defects 8                                
D/L-loop TGA 40 
D/L-loop TGA with CoA 8 
D/L-loop TGA and other heart defects 9 
Situs inversus with or without dextrocardia 4 
Dextrocardia with other heart defects 7 
Heterotaxy only 38 
MGA and other heart defects 4 
Other types of heart defects 8 
Key: ASD, atrial septal defects; VSD, ventral septal defects; AVSD, Atrioventricular Septal Defect; 
TGA, transposition of great arteris; CoA, coarctation of the aorta; MGA, malposition of great arteries 
 
3.1-PATIENT1-A206T MUTATION 
Patient 1 was diagnosed with AVSD and dextro-Transposition of the Great 
Arteries (d-TGA), referred as a complete transposition of the great arteries (Fig.3.4, 
B). Analysis of the subject’s DNA revealed a heterozygous missense mutation. The 
single-base G      A substitution, at exon position G9957689GA, and cDNA position 
615 (c.615G>A), is located in exon 5 and results in a substitution of threonine for 
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alanine at amino acid position A206T (Fig.3.2). The amino acid is located in the 
CRELD domain of CRELD1 (Fig.3.3) with extracellular function. The mutation 
changes the amino acid located at the sequon position of one of the two N-linked 
glycosylation sites of CRELD1. Glycosylation is a common post-translational 
modification for protein molecules involved in cell membrane formation. N-linked 
glycosylation requires the consensus sequence Asn-X-Ser/Thr which X can be any 
amino acid but proline. The N-linked glycosylation begins with the addition of a 14-
sugar precursor to an asparagine amino acid located at the sequon, and it allows the 
protein to fold correctly followed by further modification in the endoplasmic 
reticulum (ER) and Golgi. The first N-linked glycosylation site in CRELD1 is 
located at amino acid position 79 and the second one is at 205 (Fig.3.1). The 
mutation at this region is possibly affecting the efficiency of glycosylation. 
 
                      10                           20                        30                        40                        50                        
 MAPWPPKGLV  PAMLWGLSLF  LNLPGPIWLQ  PSPPPQSSPP  PQPHPCHTCR   
                      60                           70                        80                        90                        100                     
GLVDSFNKGL ERTIRDNFGG  GNTAWEEENL  SKYKDSETRL  VEVLEGVCSK   
                     110                         120                      130                      140                       150                      
SDFECHRLLE  LSEELVESWW  FHKQQEAPDL    FQWLCSDSLK  LCCPAGTFGP   
                     160                         170                      180                      190                       200                      
SCLPCPGGTE  RPCGGYGQCE  GEGTRGGSGH  CDCQAGYGGE  ACGQCGLGYF   
                     210                         220                      230                      240                       250                        
EAERNASHLV  CSACFGPCAR  CSGPEESNCL  QCKKGWALHH LKCVDIDECG 
                     260                         270                      280                      290                       300  
 TEGANCGADQ  FCVNTEGSYE  CRDCAKACLG  CMGAGPGRCK  KCSPGYQQVG  
                     310                         320                      330                      340                       350                       
SKCLDVDECE  TEVCPGENKQ  CENTEGGYRC  ICAEGYKQME  GICVKEQIPE   
                    360                          370                      380                      390                       400                         
SAGFFSEMTE  DELVVLQQMF  FGIIICALAT  LAAKGDLVFT  AIFIGAVAAM 
                    410                          420  
  TGYWLSERSD  RVLEGFIKGR 
 
Figure 3.1: CRELD1 protein and the relative position of amino acids. Two N-linked glycosylation 
sites are shown with the box. The amino acid change is labeled with red color. 
 31
                     A 
5’CGCAACGCCAGCCAT3’ 
    R     N      A      S      H 
                     T 
 
As seen in Fig.3.2 B, the region is conserved within human and bovine but 
different in mouse. Based on PolyPhen2 analysis this mutation is suggested to have a 
benign effect on CRELD1 protein structure. The affected subject is of Hispanic 
descent. The base substitution was not detected in 93 chromosomes from a Hispanic 
control population indicating that there is <5% chance the mutation is a 
polymorphism in that population with 95% confidence (Collins and Schwartz 2002) 
suggesting the variation is unlikely to be a polymorphism. 
 
 
 
 
 
 
 
 
 
Human QAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEES 
Bovine QAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEES 
Mouse  QAGYGGEACGQCGLGYFEAERNSSHLVCSACFGPCARCTGPEES 
 
Figure 3.2: A. Sequence analysis identifying missense mutations in CRELD1. The arrow on the 
electropherogram indicates the variant nucleotide, with the wild-type sequence shown below. The 
altered nucleotide is shown in green. The single-letter amino acid translation is under the first base of 
each codon. The altered residue is in red. Sequences from the complementary stand showed the same 
heterozygous change. B. Alignment part of the sequence of CRELD domain of human with bovine 
and mouse. 
A 
B 
 32
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3.3: A. Diagrammatic representation of CRELD1 protein (Robinson et al., 2003). The relative 
position of three amino acid changes found in heterotaxy patients are indicated by the arrows above 
the diagram of CRELD1. B. A diagrammatic representation of CRELD1 showing the predicted 
domain structure and cell membrane topology (Rupp et al., 2002).  
 
3.2-PATIENT2-T265A MUTATION 
The second alteration was found in a South Asian Indian patient with TGA, 
coarctation of aorta (CoA), AVSD, and double inlet left ventricle (DILV). The single 
base substitution of A to G at cDNA position 792 (c. A792G), was identified at exon 
7 of DNA patient. This results in a substitution of alanine for threonine at amino acid 
position 265, located in the highly conserved region of the CRELD domain (Fig.3.5, 
Extracellular Space 
R329C A206T A265T 
CRELD domain 
 
Cytoplasm 
B 
A 
EGF domains 
cb-EGF domains 
Type III transmembrane domains 
Carboxyl-terminal domain 
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A and B). The base substitution was not detected in 102 race-relevant control 
chromosomes (personal communication, Dr. Subrata K. Dey, West Bengal 
University of Technology, India). This data indicate that there is less than 5% chance 
that the mutation is a polymorphism in that population with 95% confidence (Collins 
and Schwartz, 2002) suggesting the variation is unlikely to be a polymorphism. 
Polyphen-2 analysis of mutation indicates that the mutation has a structural 
damaging effect on CRELD1 protein. 
 
 
 
Figure 3.4: Illustration of different heart defects. A. is showing AVSD also known as canal defect 
which is a defect involves holes between the two ventricles and atriums. B is showing the TGA where 
the positions of aorta and pulmonary artery have been reversed. The coarctation of aorta is illustrated 
in C. D is comparing the normal heart (on the left) with DILV (on the right) where the position of 
great vessels and ventricles are reversed and both atriums are connected to the left ventricle. 
A C B 
www.texasheartinstitute.org 
D 
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                                                                             A 
                                                   5’GCGTGAACGCTGAGG3’ 
                                                      V      N      T       E     G 
                                                                       A 
 
 
HumanLKCVDIDECGTEGANCGADQFCVNTEGSYECRDCAKACLGCMGAGP 
BovineLKCVDIDECGTERASCGADQFCVNTEGSYECRDCAKACLGCMGAGP 
MouseLKCVDIDECGTEQATCGADQFCVNTEGSYECRDCAKACLGCMGAGP 
 
Figure 3.5: A. Sequence analysis data, identifying the second missense mutation in CRELD1. The 
arrow on the electropherogram indicates the variant nucleotide, with the wild-type sequence shown 
below. The altered nucleotide is shown in green. The single-letter amino acid translation is under the 
first base of each codon. The altered residue is in red. Sequences from the complementary stand 
showed the same heterozygous change. B. Alignment of the sequence for the topological domain from 
human, bovine, and mouse CRELD1 gene. 
 
 
 
A 
B 
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3.3-PATIENT3-R329C MUTATION 
The third alteration was found in a Hispanic patient with a situs inversus, 
AVSD, and asplenia, a congenital absence of the spleen which is usually 
accompanied by complex cardiac malformations, malposition and maldevelopment 
of the abdominal organs, and abnormal location of the lungs (OMIM# 208530). The 
patient had a family history of two female siblings who died in utero. The first 
sibling was diagnosed with pulmonary artery absence (PA hypoplasia), dysplastic 
tricuspid valve, hypoplastic thymus, asplenia; the second sibling died from cystic 
hygroma, and liver calcification. No samples were available from the siblings for 
farther study. 
The mutation found in this patient results in a substitution of cysteine for 
arginine at amino acid 329 (R329C) in exon 9 which is located in a highly conserved 
region among species (Fig.3.6, A and B). This amino acid is located in the second 
calcium-binding EGF (cb-EGF) region, leading to change in β-sheet folding in the 
secondary structure of CRELD1 (Robinson et al., 2003). This is a recurrent mutation 
that has been identified in individuals with non-syndromic AVSD (Robinson et al), 
and AVSD with Down’s syndrome (Maslen et al, 2004).  The mutation was not 
detected as a polymorphism in previous studies (Robinson et al., 2003; Kusuma et 
al., 2011), and has been shown to change the protein conformation (Robinson et al., 
2003). 
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5’GCGGTTATCGCTGCA3’ 
                                                 G      Y     R     C       I 
                                                                  C 
 
Human  
Bovine  
Mouse  
 
 
Figure3.6: A. Sequence analysis data, identifying the third missense mutation in CRELD1. The arrow 
on the electropherogram indicates the variant nucleotide, with the wild-type sequence shown below. 
The altered nucleotide is shown in green. The single-letter amino acid translation is under the first 
base of each codon. The altered residue is in red. Sequences from the complementary stands showed 
the same heterozygous changes. B. Alignment part of the sequence for the topological domain from 
human, bovine, and mouse CRELD1 gene. 
 
3.4-OTHER SIGNIFICANT VARIANTS IN CRELD1 
Table 3.2 summarizes the other non-synonymous and synonymous variants 
found in this heterotaxy population. A non-synonymous variant A to G substituting 
VDECETEVCPGENKQCENTEGGYRCICAEGYKQMEGICVKEQIPESA 
VDECETAVCQGENQQCENTEGSYRCICADGYKQMEGICVKEQIPESA 
VDECETVVCPGENEKCENTEGGYRCVCAEGYRQEDGICVKEQVPESA 
 
A 
B 
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valine to methionine at amino acid position M13V is located in exon1. All patients’ 
DNA samples in this study carried this SNP variant. This SNP was found in data 
base SNP, indicating there is a polymorphism for this variant and suggesting its 
benign effect on protein structure. PolyPhen-2 analysis also suggested that the 
mutation is unlikely to change the protein structure or function. 
A two base pair GA deletion was found in chromosomes of ten patients, 
located at a non-coding sequence of CRELD1. The deletion is 52 base pairs upstream 
of the branch point located in intron eight and probably does not have a significant 
effect during splicing process. In addition, homozygous substitution of A for G at 
intron position G9957920A, located at intron 6, was detected in all of the patients’ 
DNA samples. This SNP is located thirty base pair downstream of intron/exon 
boundaries, indicating that it is unlikely to affect splicing. No data was found in 
database for this SNP. Four other known SNPs (rs279552, rs57022843, rs9853613, 
rs2302786) were also identified for which no significant effect has been reported for 
them. In addition, three other rare synonymous variants L304L, P315P, and Q368Q 
were detected. It was observed that all three amino acids coded for CRELD1 are 
highly conserved among human, mouse, and bovine.  
The first synonymous variant was detected as a heterozygous C to T silent 
mutation at L304L located at the end of the exon 8. Another heterozygous silent 
mutation was detected in three unrelated individuals. The variant was a substitution 
of A for G at amino acid position P315P. This amino acid is located at the second cb-
EGF domain of CRELD1. The last heterozygous silent mutation was found in a 
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patient, changing the base pair G to A at amino acid position Q368Q which is within 
the transmembrane domain of CRELD1. These synonymous variants were not 
further characterized, although it should be noted that synonymous SNPs can affect 
splicing via the regulation of splice enhancers or inhibitors (Parmley et al., 2006; 
Nielsen et al., 2007). 
 
Table 3.2: Synonymous and non-synonymous variants in CRELD1 found in the heterotaxy population 
Variants Location Functional group Number of patients 
 
G>GT (heterozygous) Promoter 2 at 9951009  9 
 
G>T (homozygous) Promoter 2 at 9951009  1 
T>TC (heterozygous) Promoter 2 at 9950860  3 
C>CT (heterozygous) Promoter 2 at 9950628  1 
A>G (homozygous) Exon 1, M13V  All samples (126) 
 
A>AG & A>G Intron 3 at 9954660  23% heterozygous 
11% homozygous 
G>A (homozygous) Intron 6 at 9957920  All samples (126) 
 
C>CT (heterozygous) Exon 8, L304L CRELD domain 1 
 
GA deletion Intron 8 at 9959990/1  10 
 
G>GA Exon 9, P315P cb-EGF domain 3 
 
C>CT (heterozygous) Intron 9 at 9960229  1 
 
G>GA (heterozygous) 
 
Exon 10 at Q368Q Transmembrane 1 
 This study demonstrates that there are missense mutations in 
may act to increase the likelihood of AVSD or other CHD in heterotaxy patients. In 
this study three different heterozygous missense mutations in 
identified in three unrelated individuals from a patient population of 
diagnosed with heterotaxy. Approximately 66% of the heterotaxy pop
different types of heart defect
in CRELD1 were diagnosed with different forms of heart defects in addition to 
AVSD which accounts for about 9% of patients with heterota
(Fig.4.1, B) and approximately 6.3% in total heterotaxy population used in this study. 
All three mutations were identified in highly conserved regions of 
alter CRELD1 properties.
increase the susceptibility of CHD in the heterotaxy population.
Figure 4.1: A, Approximate ratio of heterotaxy patients diagnosed with heart defects and without 
heart defects in study population. B, The ratio of different types of heart defects in heterotaxy patients 
with heart defects found in this population
66.7% 
A 
CHAPTER IV: DISCUSSION  
CRELD1
CRELD1 
126
ulation had
s (Fig.4.1, A). The three individuals carrying mutation 
xy and heart defects 
CRELD1 
 They are suggesting that mutation in CRELD1
 
   
 
33.3% 
B 
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In one case the mutation was an A to T transition in exon 5 at cDNA position 
615 (c.615A>G) that results in a substitution of threonine for alanine at amino acid 
206 (p.A206T) in the CRELD domain of CRELD1. This domain has extracellular 
function and is 333 amino acids long (p. 30-362) and contains two potential N-linked 
glycosylation sites one at amino acid position 79 and 205. N-linked glycosylation of 
some membrane proteins is critical for proper folding, co-assembly and subsequent 
trafficking through the biosynthetic pathway, suggesting that it is necessary for 
proper functional role of CRELD1. The mutation changes the amino acid located at 
sequon position of the second N-linked glycosylation site. The sequon position is 
Asn-X-Ser or Asn-X-Thr, where X is any amino acid except proline. In CRELD1 the 
sequon position is Asn-Ala-Ser. The mutation, A206T, changes the alanine to 
threonine. According to the consensus sequence X can be any amino acid except 
proline, but changes in the sequence of this sequon have shown to have a major 
effect on the ability of various tissues to utilize N-linked glycosylation signals 
(Nishikawa and Mizun, 2001).  
Therefore this alteration would not likely abolish glycosylation, but it could 
affect the efficiency. Using the bioinformatics tool, PolyPhen-2, suggests that this 
variant is unlikely to affect the protein structure. However as can be seen in Fig.4.2, 
the molecular formula for alanine is C3H7NO2. This amino acid is non-polar and 
hydrophobic and is known to be ambivalent, meaning it can be inside or outside of 
the protein molecule. On the other hand, threonine is slightly polar with a molecular 
formula of C4H9NO3, and compared to alanine it has one extra carbon and hydroxyl 
group making it a hydrophilic molecule. Although Polyphen
substitution will have a benign effect on protein structure, my analysis suggests that 
this mutation may have the potential to significantly change the protein structure. 
 
Figure 4.2: Alanine (A) and threonine
 
In addition, this non
that has extracellular function and 
affect its proper function. This alteration was not present in 
chromosomes, indicating the novelty of this mutation and suggesting an association
of risk of developing AVSD that may work in concert with addition factors such as 
heterotaxy in this study. Further study can be used to confirm our expectation
changes in protein structure by analyzing
CRELD1 in which the physical properties of mutant protein can be compared with 
wild-type CRELD1. 
The second mutation was a single base alteration of A to G at cDNA position 
792 (c. A792G) causing amino acid substitution of alanine for threonine at amino 
acid position 265 (p. T265A). This SNP is within the exon 7 and located in a highly 
A 
-2 indicates that this 
              
 (B) chemical structure. 
-synonymous variant is located in the CRELD domain 
such non-conservative alteration in CRELD1 can 
93 race-rele
 a recombinantly expressed mutant 
B 
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vant control 
 
 on 
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conserved region CRELD domain with extracellular function. Fig.4.2 shows the 
chemical structure of these two amino acids. This amino acid change will reduce the 
polarity of the protein and subsequently can alter its function. 
Based on the analysis using PolyPhen-2, this region is highly conserved 
among more than 20 different species and mutation at c.256 is predicted to have 
damaging effect on the protein structure. Although the specific effect of this mutation 
on the structure of CRELD1 is still unknown. The patient with this mutation exhibits 
a broad range of heart defects in heart valves and chambers in addition to TGA, 
AVSD, and coarctation of aorta (CoA). Race relevant population study confirmed the 
novelty of this mutation. This data is consistent with my hypothesis that there are 
mutations in CRELD1 that can increase the risk of developing CHD in heterotaxy 
population.  
The last mutation was found in a patient with situs inversus with AVSD and 
asplenia. The mutation is a C to T transition in exon 9 at cDNA position 985 (c.985 
C>T) that results in a substitution of cysteine for arginine at amino acid 329 
(p.R329C). The chemical structure of these two amino acids is shown in Fig.4.3. The 
mutation is in a very highly conserved region in the second cb-EGF domain of the 
protein. This mutation was previously detected in individuals with non-syndromic 
AVSD (Robinson et al., 2003) and AVSD with Down’s syndrome (Maslen et al., 
2006; Kusuma et al., 2011) and was determined to not be present in race-relevant 
control chromosomes indicating that it is a disease-specific mutation.  
CRELD1 has two highly 
cb-EGF domain is 41 amino acids long, 
second cb-EGF domain consists of 40 amino acids (p.305
a very specific disulfide bonding pattern which i
function (Robinson et al., 2003). Consequently, addition of a free cysteine residue, as 
occurs with this mutation, change the 
and would be expected to interfe
 
Figure 4.3: Arginine (A) and cysteine (B) chemical structure.
 
Accordingly, previous studies have shown that the p.R329C mutation alters 
the protein structure (Robinson et al.,
conserved as an arginine residue among mammals (Fig.
data suggest that the mutation 
patients. 
 
In this study 84 out of 126 (67%) 
of heart defects. Based on this study, 
A 
conserved cb-EGF domains (Fig. 3.3, B
at amino acid position 153 to 193. The 
-344). These domains have 
s essential for proper protein 
β-sheet in the secondary structure of CRELD1 
re with protein folding (Fig.4.4). 
                      
 
 2003). Furthermore, this amino acid position is 
3.6, B). Taken together,
p.R329C is involved in causing CHD in heterotaxy 
patients with heterotaxy had a 
CRELD1 mutations had a prevalence of about 
B 
 43
). The first 
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2.4% in total heterotaxy population. Identification of CRELD1 mutations in 3 out of 
84 heterotaxy patients diagnosed with broad range of CHD suggesting the prevalence 
of CRELD1 mutations appears to be approximately 3.5% in heterotaxy population 
with different types of heart defects. In addition, all three mutations were found in 
patients with heterotaxy who were also diagnosed with AVSD (3/8) suggesting a 
high prevalence of 37.5% in this portion of the population. These data suggest that 
defects in CRELD1 may contribute to the pathogenesis of AVSD and CHD in the 
context of heterotaxy. This is consistent with previous studies that demonstrated that 
CRELD1 mutations were associated with AVSD and heterotaxy as well as 
nonsyndromic AVSD (Robinson et al., 2003; Maslen, 2004). However, the high 
incidence of CRELD1 mutations in individuals with heterotaxy and AVSD indicates 
that the heterotaxy background significantly sensitizes those individuals towards 
developing an AVSD since the incidence of CRELD1mut-associated AVSD in other 
populations. 
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Figure 4.4: Diagrammatic representation of the two cb-EGF domain of CRELD1. The R329C 
mutation is indicated by the arrow. Conserved amino acidresidues defining cb-EGF domains are 
indicated by the single letter amino acid code. Black lines show the disulfide-bonding pattern for the 
conserved cysteine residues (Robinson et al., 2003).  
 
 Consequently, based on these results, I conclude that CRELD1 mutations in 
general may increase the risk for developing an AVSD and CHD in heterotaxy 
patients. However, it is very important to consider that in the process of L-R 
asymmetry and heart development, both are following a very complicated pathway 
and many factors can affect their process. The question remains as to what 
combination(s) of factors is required to exceed the threshold causing a complete 
AVSD and CHD. The results of this study support the premise that mutations in 
CRELD1 are a risk factor for AVSD and CHD in heterotaxy population.  
Previous studies suggest that combinations of rare mutations, as see in this 
study, in genes that control early embryonic L-R patterning and environmental 
factors during embryogenesis are causing most of the cases heterotaxy with heart 
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defects. Future works will have to focus on studying the other candidate genes such 
as NKX2.5 in a larger population (Belmont 2004). Such information will provide the 
factors effecting disease susceptibility in heterotaxy population. These can lead to the 
ability of early disease detection and relatively in future to therapeutic ways of 
restoring the function of altered genes. 
 
FUTURE STUDIES 
Mouse model can be used to study on how mutations in CRELD1 would 
increase the risk of developing AVSD and CHD in heterotaxy population. This can 
be done using F1 generation by crossing heterotaxy mouse Zic3(+/-) and Creld1(+/-) 
mouse and studying the rate of heart defects in their progenies. In addition, more 
study has to focus on looking for other unknown genes that increase the 
susceptibility of developing AVSD and CHD in heterotaxy. 
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Appendix: CRELD1 genomic sequence. 
acgt = R pcr primer                                                                            acgt= F pcr primer 
acgt = R seq primer                                                                            acgt= F seq primer 
CRELD1 Genomic 
 
  
9949321  ctggcctgcc tactctttgc cgctgcgctt tccctcatcc tccttctcaa aaaggatcac 
9949261  gtttctaact cttcttctct gggtctccca gacatccaca agcgctgggc cctcgtgtgg 
9949381  gcgaaaggtg agcgcttccc ggctccccat tcccctgggg gaggaccaga gtggctgtgg 
              9949441  gagttctccg agggaaagcg gcggccgagc tcactggctg cctccgcccc tctcccctaa  
              9949501  cagggtggct gaggctcttg aaacaggacg tccgctcggg gggtgagtgg gagcaagcgc 
9949561  tgggcggagg gccgcccccg gggagccagg cctgtgccag ctcacctctt ccctccccat 
9949621  ctgttttctc cggcagcggc cgccaggggc cgcgcggctc tgctcctcta ctcagccgat 
9949681  gactcgggtt tcgagcgcct ggtgggcgcc ctggcgtcgg ccctgtgcca gctgccgctg 
9949741  cgcgtggccg tagacctgtg gagccgtcgt gaactgagcg cgcaggggcc cgtggcttgg 
9949801  tttcacgcgc agcggcgcca gaccctgcag gagggcggcg tggtggtctt gctcttctct 
9949861  cccggtgcgg tggcgctgtg cagcgagtgg ctacaggatg gggtgtccgg gcccggggcg 
9949921  cacggcccgc acgacgcctt ccgcgcctcg ctcagctgcg tgctgcccga cttcttgcag 
9949981  ggccgggcgc ccggcagcta cgtgggggcc tgcttcgaca ggctgctcca cccggacgcc 
9950041  gtacccgccc ttttccgcac cgtgcccgtc ttcacactgc cctcccaact gccagacttc 
9950101  ctgggggccc tgcagcagcc tcgcgccccg cgttccgggc ggctccaaga gagagcggag 
9950161  caagtgtccc gggcccttca gccagccctg gatagctact tccatccccc ggggactccc 
9950221  gcgccgggac gcggggtggg accaggcgcg ggacctgggg cgggggacgg gacttaaata 
9950281  aaggcagacg ctgtttttct acccatgtgg cccacacgcg tctccgtttc agtggcgggg 
9950341  ctggcaaacg tcattcccta gccccgcggc cctttaaagc ccggacaggt gcagctcggt 
9950401  gccgcctctg gttggctggc gtggggtgac gtaatggcac atggcccgtc gccattggct 
9950461  gggcggcaag ctccgccccc tggactgcgg cgcgggtggg ggttgTGCGT TTTACGCAGG 
9950521  CTGTGGCAGC GACGCGGTGA GGAGACGGCC CACGGCGCCC GCGGGCTGGG GCGGTCGCTT 
9950581  CTTCCTTCTC CGTGGCCTAC GAGGgtctgg atccttctct gccggctcgt gggccgtgcc 
9950641  tttgcccttc tgcgaggccc tgaatctgat cccttccctt catatccgga tccgggctcc 
9950701  tccctccaag cccggggttc cggacacctc ccccaagaca acccctctgg cctcctctcc 
9950761  ttcagtactt ggaatctgat ctcttctccc taattctgcg gatccggccc ctaatattct 
9950821  ttatcagacc ctcagacaag aggctgactt ctgccccctt gtcaaggagc gaggccactt 
9950881  tcctctccac cccatgctag cgaggataac ttatttctct tctggaattg catcttatgc 
9950941  gcctttcccc acccatcccc acagcccctg caatacccag tttggcctct tttgcttgta 
9951001  ataacgcaga tcccagcgcc acggcacctt agaacagacc tttttctttc tcgcgtgggg 
9951061  cctgactcct tcagtgaagc ctctccacgc cctctatctg cagGTCCCCA GCCTGGGTAA 
9951121  AGATGGCCCC ATGGCCCCCG AAGGGCCTAG TCCCAGCTAT GCTCTGGGGC CTCAGCCTCT 
9951181  TCCTCAACCT CCCAGGACCT ATCTGGCTCC AGCCCTCTCC ACCTCCCCAG TCTTCTCCCC 
9951241  CGCCTCAGCC CCATCCGTGT CATACCTGCC GGGGACTGGT TGACAGCTTT AACAAGgtgg 
9951301  gtgcaccggc agcctcgtta gaggggaaca cagcgattta gagtggggaa ctctgggatg 
9951361  caaatctgcg tggatttaag tttcatcttg gtctcttact agttgtatgg ccctaggcag 
9951421  gttgcctttc tgtgcctcag tttcctagtc agtagaacag tgaagtgcta gcatgtgcca 
E1Rseq 
E1-2F 
E1Fseq 
E2Fseq 
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Pro2Fseq 
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Pro1Rseq 
Pro1F 
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Pro2F 
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9951481  ggcactgtac ttagctatta ctaattttct gtttccagGG CCTGGAGAGA ACCATCCGGG 
9951541  ACAACTTTGG AGGTGGAAAC ACTGCCTGGG AGGAAGAGAA TTTGTCCAAA TACAAAGACA 
9951601  Ggtaaggggc tgctggggga aggggtgtat attcccctcc ccgccaaatc tctgctctgc 
9951661  tggtgtaggg ctaggaactc ttggggagca cttattcatt caacaaatag cactgaacat 
9951721  ctatagtata gcagtaaaca aggcaagcaa aatgccccct tcctggagct cacattctag 
9951781  tagagaagac aagcagtgaa tgagtaagtg aataatatta tgtcagatga agaacaaaca 
9951841  gtgaagcacg gtagactgca ggacggtggg aggcaaggtg ttcaaggttt ggcatttgaa 
9951901  cagagagaca ggaagtgaag aagcgagcta tgtgacaggg agggaattgg gcagaggatg 
9951961  ggactgagct tggtgtattt gagaagtggc tggagtggag tgagccaagg ggagagtgct 
9952021  agaaggtgaa ggcaaaggct taagcctcga gggctacaga aaagagttta gatttttttt 
9952081  ggagtgtaat gggaagctct tggaaggcta tgagcagaaa aagtgatact gtcttctcta 
9952141  cacctttaaa gattactcac actgctatgt agcaaacgga ttgtaagggg caagggcgga 
9952201  ggaagcaggg agaccagttt gggaggcaag tgcatcatct aggtacaaag gcaacacaag 
9952261  ctagtgtggt atctagtgga ggacatgatg aagaggtcac agtctgggta tattttgcag 
9952321  agagaacaat aggacctggt gatagattca ttatgggtat agagaaacag tagaataaaa 
9952381  gatgcttact agattttggg cctgagcaac tgggtgagta gtgcagctgt tttctaagat 
9952441  ggtgagatgc gaaaccgaga aggtttaggg gaggggtggg atgtggtgtt ctttgaacgt 
9952501  attgggctga aatgtccatt agacatccag gtagactcca tacaaatctg gaattcagaa 
9952561  aagagtagga attggaaaca ggaatttgag agttgtcatt atatagtcag tatgtaaaga 
9952621  aagccatggg aaggatacag aaagccatta tatagtcaat atatgtaata cagaaagcca 
9952681  tttatatagt cagtatgtaa agaaaggcat gggaaggata cagaaaggcg agccctgagc 
9952741  cctccagctt ttcaaagtca gatggaagag gagtcagcaa aggctcagag ttagacctgg 
9952801  ttgtcggttc ttaacctctc agagccacag tttcttcacc tgtaaaatgg ggatattaat 
9952861  acctggtttg cctatttcat agaagtgtgg aaaaggctta actgggatgc ccactagaaa 
9952921  taaaggtttt gttattatgt aacattggtc attttctctt ttccttcgcc gggcctgagt 
9952981  ttcctcattc aggaatgagg ggattggcta agacaacccc agaggcactt ccagctttgt 
9953041  aatggctcct gcgttgcttg cttttttaaa tcacctccta tatgccaggc actgtgccag 
9953101  accctttaaa tacaggatat aagacatcaa atatttatat atgtgtgtat atatatgtgt 
9953161  gtgtgtatat atatatgtgt gtgtatatat atgtgcatat atgtctgcgt atatatatgt 
9953221  gcgtatatat atgcgtatat atatatatat atgtatatat ttgtggtaaa atacacataa 
9953281  aaaatttccc attaaagaca tttaataata tttacaatgt tgtgtaacca tcaccactat 
9953341  gtagttccag aacattttca ttaccccccc aaaaaatcct atacctatta cacagccact 
9953401  ccctattctc cccttccctc ggctcttggc aatcactaat ttgtgttagt caagcagaaa 
9953461  ttatggattt gctgatttca ttggaatcat aaaatatgtg gccttttgtg tctggctagt 
9953521  ttcacttagc ataatgtttt caaggttcac ccataccgta gcatatatca atacttattc 
9953581  ctttttatgg ctgaataata ttctcatttg gctgtaccac attttgttta accatgcatc 
9953641  agttgatgga catctgcatt gtttctacct tttggctgtt gtgaatagtg ctgctatgaa 
9953701  cattgtctac aagttttcgt ttgaacacct gttttccatt cttttgggtc tatatccagt 
9953761  agtggaattg gcaggtccta tggcaattcc atgttttact tattgaggaa ctgcttttcc 
9953821  acagtggtga tgccattttg tattcccacc tgcagtgtgg gaggattcta atttctccac 
9953881  atccctgcca acacttgtta taggatgtat ttttagccat atctacccag caagggtatt 
9953941  atattccatt gctcagatgc aggaactgat gtatgttaca acaaacctgc agggaaggta 
9954001  ttgtcatccc cattttacag atgacaaaac aaagaggttc agagaggtta agtgacttgc 
9954061  ccactagatc taccactaga tttgaaccca ggtctctctg cttcccagaa ccatgacccc 
9954121  ttccattata cctcatggcc tctcctttga tattttcacc gcacgaggaa gggtggagag 
Exon 2 
E2Rseq 
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9954181  agacttgagg agggtggtgg gtggggtggg gcatgtttcc caccagccct gccctgtccg 
9954241  atcagTGAGA CCCGCCTGGT AGAGGTGCTG GAGGGTGTGT GCAGCAAGTC AGACTTCGAG 
9954301  TGCCACCGCC TGCTGGAGCT GAGTGAGGAG CTGGTGGAGA GCTGGTGGTT TCACAAgtga 
9954361  gtggcaaagg gccttccctg gaagtgggtc acaggtgagg cctggtgata aggcctgatt 
9954421  tggccgagaa gcaggggggt gcatgctggg gcccatgtcc tggttgtgct ccttccaaac 
9954481  ccaggtctgc taagaacttg ccgggggact tgcgctccac tttgagcctc agtttaccct 
9954541  tctgccaaat ggggaaaggg cattggtcag atggcctttt gggtcttatg tccaagctgg 
9954601  gttgaatcac agattcaggc atgggggaat gggaacagca cttatgacac tatctcagca 
9954661  cctcctcccc acctccctcc accctgcccc tgcctcagGC AGCAGGAGGC CCCGGACCTC 
9954721  TTCCAGTGGC TGTGCTCAGA TTCCCTGAAG CTCTGCTGCC CCGCAGGCAC CTTCGGGCCC 
9954781  TCCTGCCTTC gtgagttttt aagttgctct tggggatggg aggggaccac cgagtccagg 
9954841  gatccagtcc tggctctgtc cctagttcgc tgtgtgaact caggctactc agataaactt 
9954901  ctctggacct cagttcttgc ctgcctgaca gggctgggga gatgggcaaa tcagtgggga 
9954961  aaggcttgga gaaagcacag gggctagact gagtcatatg cagtatagtt atcatcatgt 
9955021  actaaagaaa tgatagactt cccagcccct tcatttccca tgccagatcg gactatggta 
9955081  ccttcctggg gaggggcggg tgctgacctg gagcctccat gatcgccatc catcctcaca 
9955141  cacagtcctg gcacaagagc tgaacttact accagcctct tttagagcag tctttcctga 
9955201  agctacagat aaagagctag ctacaaagat ggcaaattca gtctttgtaa aagaaaatat 
9955261  tggctgggcg cggtggctca cacctgtaat cccaacactt tgggaggctg cggtgggtgg 
9955321  atcatgaggt caggagatcg agaccatcgt ggctatcatg gtgaaacacc gtctctacta 
9955381  aaaaatacaa aaaattagcc gggcatggtg gcgggcgcct ctagtcccag ctactctgga 
9955441  ggctgaggca gaagaatggc atgaacccgg caggcggagc ttgcagtgag ccgagatcat 
9955501  gccactgcac tccagcctgg gcgacagagc gagactctgt ctcaaaaaaa aaaaagaaaa 
9955561  tatttggtcc agtggctcgt acctgtaaac ccagcacttt gggaggctga ggcaggagga 
9955621  tcacttgagg ccaggagttt gagagaccag cctgggtagt agagcaagac cctgtctctt 
9955681  aaaaaaaaaa tagtggggca tggtagtgca gcctgttgtt cccctaggct gaggtgggag 
9955741  gattgcttga gcccaggagt tcgaagctgc agtgagctat gatcatgtca ttgcctggga 
9955801  aacagagcga gaccctgtca ctaaaaataa ataaataaat aaataaataa ataaataaat 
9955861  aaataaataa aaggtctgta aaatctaatt gttccacaag aggaaattgg ttaagtaaat 
9955921  gtcagtttta tgacaaaata ttatgtcatt aaaattaatt ttcttctcca aaaatgttta 
9955981  ctgatatgca gagcagaaaa tattatcttg ttttttttgt ttttttgtct tttttattga 
9956041  tcattcttgg gtgtttctcc cagaggggga tttggcaggg tcataggaca atagtggagg 
9956101  gaaggtcagc agataaacaa gtgaacaaag gtctctggtt ttcctaggca gaggaccctg 
9956161  cggccttccg cagtgtttgt gtccctgggt acttgagatc aaggagtggt gatgactctc 
9956221  aaccagcatg ctgccttcaa gcatctgttt aacaaagcac atcttgcacc gcccttaatc 
9956281  catttaaccc tgagtggaca cagcacatgt ttcagagagc acagggttgg ggataaggtc 
9956341  atagatcaac aggatcccaa ggcagaagaa tttttcttag tacagaacaa aatgaaaagt 
9956401  ctcccgtgtc tacttctttc tacacagaca cagcaaccat ccgatttctc agtgttttcc 
9956461  ccacctttcc cccttttcta ttccacaaaa ccgccattgt catcctggcc cgttctcaat 
9956521  gagctgttgg gtacacctcc cagacggggt ggtggccggg cagaggggct cctcacttcc 
9956581  cagtaggggc agccgggcag aggcgcccct cacctcccgg acggggcggc tggccgggcg 
9956641  gggggctgac cccctcacct ccctcccgga cgggctggct gcccggcgga gacacttctc 
9956701  acttcccaga cggggcggct gccgggcgga ggggctcctc acttctcaga cagggcggcc 
9956761  gggcagagac gctcctcacc tcccagacgg ggtcgcggcc gggcagagac gctcctcact 
9956821  tcctagatgg gatggcggcc gggcagagac gctcctcact ttccagactg ggcagcctgg 
Exon 3 
Exon 4 
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9956881  cagagaggct cctcatatcc cagacgatgg gccgccaggc agagacgctc ctcacttccc 
9956941  agacggggtg gtggccgggc agaggctgca atctcggcac tttgggaggc caaggcaggc 
9957001  ggctgggagg tggaggttgt agcgagccga gatcacgcca ctgcactcca gcctgggcac 
9957061  cattgagcac tgagtgaacg agactccgtc tgcaatcccg gcacctcggg aggccgaggc 
9957121  tggcggatca ctcgcgttta ggagctggag accggcccgg ccaacacagc gaaaccccgt 
9957181  ctccaccaaa aaaatacgaa aaccagtcag gcgtggtggc gcgcgcctgc aatcgcaggc 
9957241  actcggcagg ttgaggcagg agaatcaggc agggaggttg cagtgagccg agatggcagc 
9957301  agtacagtcc agcttcagct tggcatcaga gggagaccgt gtaaagagag ggagagggag 
9957361  accatgggga gagggagagg gaggccatgg ggagagggag agggaaaggg ggagggggag 
9957421  gggagggggg gagggaggga aggcaaggga gagggagagg gagagggaga aaatattatc 
9957481  ttgtatatca aggttgtata gatgacctca cctggtttgg tgtcttccca cagCCTGTCC 
9957541  TGGGGGAACA GAGAGGCCCT GCGGTGGCTA CGGGCAGTGT GAAGGAGAAG GGACACGAGG 
9957601  GGGCAGCGGG CACTGTGACT GCCAAGCCGG CTACGGGGGT GAGGCCTGTG GCCAGTGTGG 
9957661  CCTTGGCTAC TTTGAGGCAG AACGCAACGC CAGCCATCTG GTATGTTCGG gtaggtagcc 
9957721  aaaaggtgtg gcactgggca ggggcagatg gggcacctgc ctgcccatcc tcatgctgcc 
9957781  cccattccac ccagCTTGTT TTGGCCCCTG TGCCCGATGC TCAGGACCTG AGGAATCAAA 
9957841  CTGTTTGCAA TGCAAGAAGG GCTGGGCCCT GCATCACCTC AAGTGTGTAG gtaagtgggg 
9957901  ccctagctag gtctgggaag atggtcaggg gcctgggctt ggtcctttat tctctcaaca 
9957961  caagcctggg ctagactagc ctagtctcca ccttcatgga gatctcaacc tggctgggaa 
9958021  ggcagaaaag taaccagata cttacagtcc agtacacagg tactgtgtag tatagtccct 
9958081  gtgtacagtg agagatgcct ctgatctagt tcagtggaag tggtgatggg gaatcaggaa 
9958141  aggcttcttg gaggaggcgt tactttggcc aagtcctaaa aattgaggaa ggggctgggc 
9958201  gcggtggctc acgcctgtaa tcccagcact ttgggaggcc aaggcgggca gatcatgaga 
9958261  tcaggagatc gagaccatcc tggctaacat ggtgaaaccc tgtctcaact aaaaatacaa 
9958321  aaaattagct gggcgtggtg gcgggtgcct gtagtcccag ctactcagga ggctgaggca 
9958381  ggagaagggc atgaacctgg gaggcggagc ttgcagtgag ccgagatcgc accactgcac 
9958441  tccagtctgg gcaacagagg gagactccat ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa 
9958501  tgaggaaggg ttggctagga gaatgaggac actgaacttg gggtcaggaa acctgggttc 
9958561  aagacttggt ttggtcccag cctagccact tatatagact aaagtaaagg ctaagctgct 
9958621  gtaacaaaaa tccccaaaag actgtggctt aaagagtata gaggttggct gggtgtggta 
9958681  gctcactcac gcctctaatc ccagcacttt gagaggctga agtggggtgg atcacctgag 
9958741  gtcaggagtt cgagaccagc ctggccaaca tggcaaaacc ctgtctgtac taaaaataca 
9958801  aaaatttagc caggcatggt ggcaggtgcc tgtaatccca gctactcggg aggcagaggc 
9958861  aggagagtcg cttgaatcca ggaggcagag gttgcagtga gccaagatca caccattgca 
9958921  ctctagcctg ggtgacaaga gcgaaactcc atctcaaaaa aaaaaaaaag aatctagagg 
9958981  gtagaggttt attttttttt atcatattac agtcccaaag tgagtagtcc aggctggcag 
9959041  gggagctctg ctagtcataa tcattccagt acccagatta ttcctgtaac ttactgcaca 
9959101  atcatcccct tgggcgttgt ctgcatggtt gaagctgagt cctgggcatc tctgtgtccc 
9959161  acatgccagc actcaggaag ggagaaggga aagaaagtgc attgaggagt ccaagcattg 
9959221  ttttaagacc aagctaacgg tggagctcat cactcctgtt tacatcctgt tggccagaac 
9959281  tcaatcacag ggacacactt agcttcaaga caggttggca aatgtggtct ctggctgggc 
9959341  agcctgaagt ccagctagtc tgcttctgtg ttggtagaca gcttgcagtc tctgccatac 
9959401  catttaatcc caggcaagac cattccccaa cggctctggc ttcagcttcc ctactaaata 
9959461  gggattgaaa ttctcaccct gctcacctct ctgcagACAT TGATGAGTGT GGCACAGAGG 
9959521  GAGCCAACTG TGGAGCTGAC CAATTCTGCG TGAACACTGA GGGCTCCTAT GAGTGCCGAG 
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9959581  gtcagtgtct acttctgcag aggaggggac gtgaggagtg gaggaagagc tgctccacac 
9959641  ctgtccctcc aaaccttccc cttctcaggc ttcagagcac ccccaggcct ccgcttctgg 
9959701  agcgtggctc ccctgggcct aggtgcacat ctcaccctca tctttctctc ctctctccag 
9959761  ACTGTGCCAA GGCCTGCCTA GGCTGCATGG GGGCAGGGCC AGGTCGCTGT AAGAAGTGTA 
9959821  GCCCTGGCTA TCAGCAGGTG GGCTCCAAGT GTCTCGgtga gtctcctgct gatgggacac 
9959881  aggcacctgg gagtgcctca cccagcatga atggtgaaga ggctggaata tgggcaggtg 
9959941  ggggaaggaa gggtggaatg ttgcctgggc aagggcagag gggagtgttg agagatggac 
9960001  aagatggagt cagggtgctg ggtggggggc cctagcagga ctctgacccc tccctcccct 
9960061  caagATGTGG ATGAGTGTGA GACAGAGGTG TGTCCGGGAG AGAACAAGCA GTGTGAAAAC 
9960121  ACCGAGGGCG GTTATCGCTG CATCTGTGCC GAGGGCTACA AGCAGATGGA AGGCATCTGT 
9960181  GTGAAGGAGC AGATCCCAGg tgagccctgg ggcgggagag gggaggtcct cattcaaaga 
9960241  gaaggcaggc aagccccttc cccaggtagc agtggcagct ccaggccctg ccccatccct 
9960301  actgccaccc agccccctgg aggctgcact gagaccgggc tctacatctg atctccaggt 
9960361  tggctctcag cagccttata ccttccaggg tacaaaggga atcagacctg gcatcaaatc 
9960421  agtctgcctc cttaacctgt ttcctcatct atccaatggg accagtgttt gccctggcct 
9960481  gctgagagct gtcctaggcc gggggtgtgg tgagatgcag ggtaatcaca acgatgatgg 
9960541  cagggaccat ttccccagca attactgtgt cagatgctgt tctagGTGCA TTCCCCATCT 
9960601  TAACTGATTT AACCCCTGAA ACAACCCGAC GCTGGAAGTT GGGTTCTCAT CCCCACTCTA 
9960661  CATATGTAAA AATGAAGATG CAGAGAGATG AAGCTACTTT CCCAGGGCTA TATGGCAAGC 
9960721  AAGTCGCAAA GCTGGGATCC CAATCCAGAC AGTCTGACCG TGGAACGAGA CTCATACACg 
9960781  taataaatgc tctgccccca acttgtccac cacatggcct tggcaagtcc aaccccttta 
9960841  cctctctgag cctcactttc ccatttagtg agacagggat ggtaactgcc ccttgcaggg 
9960901  tggttttgag cagtaaatgt agtgtgcctg gcttgctggg caggcctggt ggccatgatg 
9960961  atcaggtgtg tgggagttct ggggagactc caagaactac caggaacagg gatacgagtg 
9961021  ccaggctgca tctcttgctc ctctgcagAG TCAGCAGGCT TCTTCTCAGA GATGACAGAA 
9961081  GACGAGTTGG TGGTGCTGCA GCAGATGTTC TTTGGCATCA TCATCTGTGC ACTGGCCACG 
9961141  CTGGCTGCTA AGGGCGACTT GGTGTTCACC GCCATCTTCA TTGGGGCTGT GGCGGCCATG 
9961201  ACTGGCTACT GGTTGTCAGA GCGCAGTGAC CGTGTGCTGG AGGGCTTCAT CAAGGGCAGA 
9961261  TAATCGCGGC CACCACCTGT AGGACCTCCT CCCACCCACG CTGCCCCCAG AGCTTGGGCT 
9961321  GCCCTCCTGC TGGACACTCA GGACAGCTTG GTTTATTTTT GAGAGTGGGG TAAGCACCCC 
9961381  TACCTGCCTT ACAGAGCAGC CCAGGTACCC AGGCCCGGGC AGACAAGGCC CCTGGGGTAA 
9961441  AAAGTAGCCC TGAAGGTGGA TACCATGAGC TCTTCACCTG GCGGGGACTG GCAGGCTTCA 
9961501  CAATGTGTGA ATTTCAAAAG TTTTTCCTTA ATGGTGGCTG CTAGAGCTTT GGCCCCTGCT 
9961561  TAGGATTAGG TGGTCCTCAC AGGGGTGGGG CCATCACAGC TCCCTCCTGC CAGCTGCATG 
9961621  CTGCCAGTTC CTGTTCTGTG TTCACCACAT CCCCACACCC CATTGCCACT TATTTATTCA 
9961681  TCTCAGGAAA TAAAGAAAGG TCTTGGAAAG TTAAAAGGCA TCAGTCTTAC TACCTGTCCC 
9961741  ACCACCCCCA CCTTAGGGAA ATGTCCTAGA ATCCTGGGAA ATTGAGGGCT TCTTTGATGG 
9961801  TGAGTGGAGA AAAGATAGAG GAGAAGGTTG CCCCTGAAGT GCTGTTAGGA GAAGGAGGAT 
 9961861  AGAGGAATCA GCCTTAGGAG GGTTCCATGC CAGCTGTCAT TTGGCAAAGG ACCCTGGACA  
9961921  GATGACTTTT GCCTCTGAAC TTCACTCTTC TCTTTCCTCA AATGGGCTTC ATAATGCTTT 
9961981  CCACTCAGGC TTAACATGAG AATTAAATGA GGTGACAAAT GTGAAGACCT GGACAGTACA 
              9962041  CAACAGATAT TCAATAAAAG TGTGGTCGCC ATTATGACCA GAGCCTCCAA 
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Translation (NP_056328.2 and NP_001070883.1) 
MAPWPPKGLVPAMLWGLSLFLNLPGPIWLQPSPPPQSSPPPQPHPCHTCRGLVDSFNKGL 
ERTIRDNFGGGNTAWEEENLSKYKDSETRLVEVLEGVCSKSDFECHRLLELSEELVESWW 
FHKQQEAPDLFQWLCSDSLKLCCPAGTFGPSCLPCPGGTERPCGGYGQCEGEGTRGGSGH 
CDCQAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEESNCLQCKKGWALHH 
LKCVDIDECGTEGANCGADQFCVNTEGSYECRDCAKACLGCMGAGPGRCKKCSPGYQQVG 
SKCLDVDECETEVCPGENKQCENTEGGYRCICAEGYKQMEGICVKEQIPESAGFFSEMTE 
DELVVLQQMFFGIIICALATLAAKGDLVFTAIFIGAVAAMTGYWLSERSDRVLEGFIKGR 
X 
